AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 2144796 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinidine therapy
Number of subjects: 808
Study 2144796 — intervention group
Group type: COMPARATOR
Intervention: Control group (no antiarrhythmic therapy)
Number of subjects: 808
Study 7001961 — intervention group
Group type: EXPERIMENTAL
Intervention: Flunisolide (inhaled steroid)
Number of subjects: 0
Study 7001961 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 31715161 — intervention group
Group type: EXPERIMENTAL
Intervention: Broad-spectrum combination empiric antibiotics
Number of subjects: 29
Study 31715161 — intervention group
Group type: EXPERIMENTAL
Intervention: Confirmed sepsis at admission
Number of subjects: 29
Study 31715161 — intervention group
Group type: EXPERIMENTAL
Intervention: Trauma patients
Number of subjects: 29
Study 31715161 — intervention group
Group type: EXPERIMENTAL
Intervention: Clostridium difficile enteritis
Number of subjects: 29
Study 31715161 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospitalization
Number of subjects: 29
Study 31715161 — intervention group
Group type: EXPERIMENTAL
Intervention: Mortality
Number of subjects: 29
Study 29506014 — intervention group
Group type: EXPERIMENTAL
Intervention: Milking Maneuver (MM)
Number of subjects: 138
Study 29506014 — intervention group
Group type: COMPARATOR
Intervention: Early cord clamping
Number of subjects: 138
Study 27720404 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical Video Coaching (SVC) group, n = 14
Number of subjects: 28
Study 27720404 — intervention group
Group type: COMPARATOR
Intervention: Control group, n = 14
Number of subjects: 28
Study 27720404 — intervention group
Group type: EXPERIMENTAL
Intervention: SVC group satisfaction survey
Number of subjects: 28
Study 25939614 — intervention group
Group type: EXPERIMENTAL
Intervention: Antipsychotic augmentation (quetiapine, risperidone, aripiprazole, olanzapine, paliperidone, haloperidol)
Number of subjects: 491
Study 25939614 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole
Number of subjects: 491
Study 25939614 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol
Number of subjects: 491
Study 25939614 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 491
Study 25939614 — intervention group
Group type: COMPARATOR
Intervention: Antipsychotics
Number of subjects: 491
Study 25939614 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 491
Study 23124798 — intervention group
Group type: EXPERIMENTAL
Intervention: Postpartum depressive symptoms measured by the Edinburgh Postnatal Depression Scale (EPDS) at 4-15 weeks postpartum, with a score ≥9 indicating depressive symptoms.
Number of subjects: 71
Study 23124798 — intervention group
Group type: EXPERIMENTAL
Intervention: Cesarean delivery
Number of subjects: 71
Study 23124798 — intervention group
Group type: EXPERIMENTAL
Intervention: Gestational weight gain
Number of subjects: 71
Study 21044166 — intervention group
Group type: EXPERIMENTAL
Intervention: Implant-cantilever group (1 implant with cantilever)
Number of subjects: 10
Study 21044166 — intervention group
Group type: COMPARATOR
Intervention: Implant-implant group (2 adjacent implants)
Number of subjects: 10
Study 19739431 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciclesonide hydrofluoroalkane nasal aerosol 300 microg
Number of subjects: 0
Study 19739431 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciclesonide hydrofluoroalkane nasal aerosol 150 microg
Number of subjects: 0
Study 19739431 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciclesonide hydrofluoroalkane nasal aerosol 75 microg
Number of subjects: 0
Study 19739431 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciclesonide hydrofluoroalkane nasal aerosol (all doses)
Number of subjects: 0
Study 19739431 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 17531578 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan 8 mg/day for 3 to 6 weeks before and 16 mg/day for 6 months after electrical cardioversion
Number of subjects: 171
Study 17531578 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 171
Study 15768732 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotics (1.2g/d) and soluble fiber (11g/d) with L-Glutamine (30g/d) if diarrhea persisted at week 4
Number of subjects: 35
Study 15768732 — intervention group
Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 35
Study 11328258 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg
Number of subjects: 36
Study 11328258 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 40 mg
Number of subjects: 36
Study 11328258 — intervention group
Group type: COMPARATOR
Intervention: Lansoprazole 30 mg
Number of subjects: 36
Study 9740159 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual biopsy using a 14 G Tru-cut needle (group 1, 67 patients)
Number of subjects: 166
Study 9740159 — intervention group
Group type: COMPARATOR
Intervention: Automated biopsy using an 18 G gun (group 2, 99 patients)
Number of subjects: 166
Study 8046601 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbamazepine (CBZ) monotherapy
Number of subjects: 22
Study 8046601 — intervention group
Group type: COMPARATOR
Intervention: Comparison estimates assuming a constant concentration/dose ratio
Number of subjects: 22
Study 2737271 — intervention group
Group type: EXPERIMENTAL
Intervention: Formoterol (12 micrograms twice daily)
Number of subjects: 20
Study 2737271 — intervention group
Group type: COMPARATOR
Intervention: Salbutamol (200 micrograms twice daily)
Number of subjects: 20
Study 2737271 — intervention group
Group type: EXPERIMENTAL
Intervention: Formoterol
Number of subjects: 20
Study 31833144 — intervention group
Group type: EXPERIMENTAL
Intervention: Abused women
Number of subjects: 2621
Study 31833144 — intervention group
Group type: COMPARATOR
Intervention: Non-abused women
Number of subjects: 2621
Study 29278659 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower levels of serum exosomal miR-638
Number of subjects: 0
Study 29278659 — intervention group
Group type: EXPERIMENTAL
Intervention: Over-expression of miR-638 in Huh7 and SMCC7721 HCC cells
Number of subjects: 0
Study 29278659 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum exosomal miR-638 levels
Number of subjects: 0
Study 27939076 — intervention group
Group type: EXPERIMENTAL
Intervention: Simtuzumab (125 mg/mL, subcutaneously once a week)
Number of subjects: 544
Study 27939076 — intervention group
Group type: COMPARATOR
Intervention: Placebo (subcutaneously once a week)
Number of subjects: 544
Study 27939076 — intervention group
Group type: EXPERIMENTAL
Intervention: Simtuzumab and Placebo
Number of subjects: 544
Study 26700866 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified unconditional cash transfer (21,500 FCFA/month for 5 months, 22,500 FCFA in June)
Number of subjects: 3500
Study 26700866 — intervention group
Group type: COMPARATOR
Intervention: Standard unconditional cash transfer (32,500 FCFA/month for 4 months)
Number of subjects: 3500
Study 23172028 — intervention group
Group type: EXPERIMENTAL
Intervention: Original manufacturer-supplied cuff
Number of subjects: 54
Study 23172028 — intervention group
Group type: COMPARATOR
Intervention: Washable replacement cuff
Number of subjects: 54
Study 21303934 — intervention group
Group type: EXPERIMENTAL
Intervention: Problem-solving therapy (PST) delivered via videophones
Number of subjects: 42
Study 18311597 — intervention group
Group type: EXPERIMENTAL
Intervention: Kaohsiung, Taiwan students
Number of subjects: 0
Study 18311597 — intervention group
Group type: COMPARATOR
Intervention: Nanjing, China students
Number of subjects: 0
Study 16782715 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac Resynchronization Therapy (CRT)
Number of subjects: 813
Study 16782715 — intervention group
Group type: COMPARATOR
Intervention: Medical therapy
Number of subjects: 813
Study 12622106 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-controlled propofol combined with midazolam
Number of subjects: 40
Study 12622106 — intervention group
Group type: COMPARATOR
Intervention: Target-controlled infusion of propofol combined with midazolam
Number of subjects: 40
Study 10229290 — intervention group
Group type: EXPERIMENTAL
Intervention: Active smoking
Number of subjects: 0
Study 10229290 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive smoking
Number of subjects: 0
Study 10229290 — intervention group
Group type: EXPERIMENTAL
Intervention: No identifiable source of exposure
Number of subjects: 0
Study 10229290 — intervention group
Group type: COMPARATOR
Intervention: Correlation with HbA1c, BMI, and deprivation scores
Number of subjects: 0
Study 8983891 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy with FEM (5‐fluorouracil 600 mg/m2/day i.v. on days 1, 8, 29 and 36, epirubicin 45 mg/m2/day i.v. on days 1 and 29, mitomycin C 10 mg/m2 i.v. on day 1, repeated every 56 days for 3 cycles)
Number of subjects: 84
Study 8983891 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 84
Study 8983891 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy with FEM (specifically for histologic grade III tumors)
Number of subjects: 84
Study 8983891 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy with FEM
Number of subjects: 84
Study 1753046 — intervention group
Group type: EXPERIMENTAL
Intervention: Nursing Home Care Unit (NHCU) teaching sessions
Number of subjects: 106
Study 1753046 — intervention group
Group type: COMPARATOR
Intervention: Control sessions in acute care wards
Number of subjects: 106
Study 6751510 — intervention group
Group type: EXPERIMENTAL
Intervention: gentamicin-betamethasone ointment
Number of subjects: 46
Study 6751510 — intervention group
Group type: EXPERIMENTAL
Intervention: gentamicin alone
Number of subjects: 46
Study 6751510 — intervention group
Group type: COMPARATOR
Intervention: placebo ointment
Number of subjects: 46
Study 31690561 — intervention group
Group type: EXPERIMENTAL
Intervention: Stand alone VR (six week, internet based intervention with weekly online sessions and daily exercises)
Number of subjects: 322
Study 31690561 — intervention group
Group type: EXPERIMENTAL
Intervention: Blended VR (same internet based intervention supplemented by face-to-face physiotherapy support)
Number of subjects: 322
Study 31690561 — intervention group
Group type: EXPERIMENTAL
Intervention: Stand alone VR
Number of subjects: 322
Study 31690561 — intervention group
Group type: EXPERIMENTAL
Intervention: Blended VR
Number of subjects: 322
Study 31690561 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 322
Study 28652293 — intervention group
Group type: EXPERIMENTAL
Intervention: interface‐focused educational intervention
Number of subjects: 33
Study 25545744 — intervention group
Group type: EXPERIMENTAL
Intervention: Green Tea (GT)
Number of subjects: 113
Study 25545744 — intervention group
Group type: EXPERIMENTAL
Intervention: Black Tea (BT)
Number of subjects: 113
Study 25545744 — intervention group
Group type: COMPARATOR
Intervention: Water (Control)
Number of subjects: 113
Study 23397347 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral vitamin A (7500 μg) once a week
Number of subjects: 581870
Study 23397347 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 581870
Study 21251187 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonography (US) guidance for puncture in addition to fluoroscopy
Number of subjects: 224
Study 21251187 — intervention group
Group type: COMPARATOR
Intervention: Fluoroscopy-guided renal access
Number of subjects: 224
Study 19809026 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous infusions of Fe(III)-hydroxide sucrose (200 mg) on the third day of hypoxia
Number of subjects: 33
Study 19809026 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous infusions of Fe(III)-hydroxide sucrose (400 mg) after venesection
Number of subjects: 33
Study 19809026 — intervention group
Group type: COMPARATOR
Intervention: Venesection of 2 L of blood (iron depletion)
Number of subjects: 33
Study 17580441 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupoint‐catgut‐embedding
Number of subjects: 80
Study 17580441 — intervention group
Group type: COMPARATOR
Intervention: Acupuncture
Number of subjects: 80
Study 15101309 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferrule group
Number of subjects: 0
Study 15101309 — intervention group
Group type: COMPARATOR
Intervention: Nonferrule group
Number of subjects: 0
Study 11470688 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Dk RGP lenses for 12 months of 6-nights/week EW
Number of subjects: 201
Study 11470688 — intervention group
Group type: COMPARATOR
Intervention: Medium-Dk RGP lenses for 12 months of 6-nights/week EW
Number of subjects: 201
Study 11251357 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged prophylaxis with low-molecular-weight heparin (LMWH)
Number of subjects: 0
Study 11251357 — intervention group
Group type: EXPERIMENTAL
Intervention: Cost of administering LMWH (including teaching self-administration and follow-up visit)
Number of subjects: 0
Study 9503532 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate (ID) administered for 3 weeks, 4 times a day
Number of subjects: 18
Study 9503532 — intervention group
Group type: EXPERIMENTAL
Intervention: Molsidomine (M) administered for 3 weeks, 4 times a day
Number of subjects: 18
Study 9503532 — intervention group
Group type: COMPARATOR
Intervention: Comparison of efficacy after 3 weeks of regular intake
Number of subjects: 18
Study 8458187 — intervention group
Group type: EXPERIMENTAL
Intervention: sorbinil
Number of subjects: 16
Study 8458187 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 16
Study 3757766 — intervention group
Group type: EXPERIMENTAL
Intervention: Methadone
Number of subjects: 0
Study 3757766 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine
Number of subjects: 0
Study 3757766 — intervention group
Group type: EXPERIMENTAL
Intervention: Heroin
Number of subjects: 0
Study 3757766 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30115593 — intervention group
Group type: EXPERIMENTAL
Intervention: Temozolomide (150-200 mg/m2, orally) monotherapy on days 1-5 every 4 weeks for a maximum of 12 cycles
Number of subjects: 155
Study 30115593 — intervention group
Group type: COMPARATOR
Intervention: Bevacizumab (10 mg/kg, intravenously) in combination with temozolomide (150-200 mg/m2, orally)
Number of subjects: 155
Study 30115593 — intervention group
Group type: EXPERIMENTAL
Intervention: Temozolomide monotherapy
Number of subjects: 155
Study 30115593 — intervention group
Group type: COMPARATOR
Intervention: Bevacizumab and temozolomide combination
Number of subjects: 155
Study 27695978 — intervention group
Group type: EXPERIMENTAL
Intervention: Red spinach extract (RSE) 1000 mg dose; 90 mg nitrate
Number of subjects: 15
Study 27695978 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PBO)
Number of subjects: 15
Study 27695978 — intervention group
Group type: EXPERIMENTAL
Intervention: Red spinach extract (RSE)
Number of subjects: 15
Study 27695978 — intervention group
Group type: COMPARATOR
Intervention: Red spinach extract (RSE) and Placebo (PBO)
Number of subjects: 15
Study 23843470 — intervention group
Group type: EXPERIMENTAL
Intervention: HIT-6 questionnaire
Number of subjects: 490
Study 23291073 — intervention group
Group type: EXPERIMENTAL
Intervention: Irinotecan plus cisplatin (IP regimen)
Number of subjects: 63
Study 23291073 — intervention group
Group type: COMPARATOR
Intervention: Gemcitabine plus cisplatin (GP regimen)
Number of subjects: 63
Study 20055772 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiparkinson drug treatment
Number of subjects: 0
Study 20055772 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy subjects)
Number of subjects: 0
Study 19057272 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib 400 mg orally twice daily + Docetaxel 75 mg/m2 intravenously on a 21-day cycle
Number of subjects: 20
Study 19057272 — intervention group
Group type: COMPARATOR
Intervention: Docetaxel alone
Number of subjects: 20
Study 16176006 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycerol test during the period of onset
Number of subjects: 72
Study 16176006 — intervention group
Group type: COMPARATOR
Intervention: Glycerol test during the period of intermission
Number of subjects: 72
Study 12207638 — intervention group
Group type: EXPERIMENTAL
Intervention: Saquinavir soft-gel formulation (1200 mg three times daily) plus rifabutin (300 mg once daily)
Number of subjects: 14
Study 12207638 — intervention group
Group type: COMPARATOR
Intervention: Rifabutin (300 mg once daily) alone
Number of subjects: 14
Study 10335967 — intervention group
Group type: EXPERIMENTAL
Intervention: iodixanol 270 mg I/ml
Number of subjects: 50
Study 10335967 — intervention group
Group type: COMPARATOR
Intervention: iohexol 300 mg I/ml
Number of subjects: 50
Study 8944373 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole 30 mg daily (LAN30)
Number of subjects: 211
Study 8944373 — intervention group
Group type: COMPARATOR
Intervention: Omeprazole 40 mg daily (OME40)
Number of subjects: 211
Study 2011924 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard-dose alpha-IFN (3 MU/day i.m. for 6 months, then 3 MU three times/week for a further 6 months)
Number of subjects: 24
Study 2011924 — intervention group
Group type: COMPARATOR
Intervention: Low-dose alpha-IFN (1.5 MU/day with the same schedule and for the same period)
Number of subjects: 24
Study 2011924 — intervention group
Group type: COMPARATOR
Intervention: Low-dose alpha-IFN
Number of subjects: 24
Study 29797695 — intervention group
Group type: EXPERIMENTAL
Intervention: Theobromine (500 mg d‐1 for 4 weeks)
Number of subjects: 44
Study 29797695 — intervention group
Group type: COMPARATOR
Intervention: Placebo (500 mg d‐1 for 4 weeks)
Number of subjects: 44
Study 29797695 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat meal
Number of subjects: 44
Study 27924138 — intervention group
Group type: EXPERIMENTAL
Intervention: MIPS (NO‐Shotgun®)
Number of subjects: 8
Study 27924138 — intervention group
Group type: COMPARATOR
Intervention: Control (isocaloric maltodextrin placebo)
Number of subjects: 8
Study 24850540 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional tasks exercise group (n = 43)
Number of subjects: 83
Study 24850540 — intervention group
Group type: COMPARATOR
Intervention: Active cognitive training group (n = 40)
Number of subjects: 83
Study 22223077 — intervention group
Group type: EXPERIMENTAL
Intervention: Left anodal-right cathodal tDCS modulation
Number of subjects: 0
Study 22223077 — intervention group
Group type: EXPERIMENTAL
Intervention: Left cathodal-right anodal tDCS modulation
Number of subjects: 0
Study 22223077 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 0
Study 19949906 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxidized zirconium femoral component
Number of subjects: 100
Study 19949906 — intervention group
Group type: COMPARATOR
Intervention: Cobalt-chrome femoral component
Number of subjects: 100
Study 19949906 — intervention group
Group type: EXPERIMENTAL
Intervention: Both components
Number of subjects: 100
Study 18457473 — intervention group
Group type: EXPERIMENTAL
Intervention: Belimumab
Number of subjects: 449
Study 18457473 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 449
Study 16647506 — intervention group
Group type: EXPERIMENTAL
Intervention: Two doses of Simulect (20 mg intravenously per dose, one given 2 hours before transplantation and the second on day 4 posttransplant)
Number of subjects: 52
Study 16647506 — intervention group
Group type: COMPARATOR
Intervention: Single dose of Simulect (exact dosage not specified)
Number of subjects: 52
Study 14653294 — intervention group
Group type: EXPERIMENTAL
Intervention: 330‐carbide bur
Number of subjects: 90
Study 14653294 — intervention group
Group type: EXPERIMENTAL
Intervention: 330 fine‐grit diamond bur
Number of subjects: 90
Study 14653294 — intervention group
Group type: EXPERIMENTAL
Intervention: 330 medium‐grit diamond bur
Number of subjects: 90
Study 14653294 — intervention group
Group type: COMPARATOR
Intervention: Control (enamel margins)
Number of subjects: 90
Study 10793015 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron (8 mg) three times daily for 2 weeks
Number of subjects: 16
Study 10793015 — intervention group
Group type: COMPARATOR
Intervention: Placebo three times daily for 2 weeks
Number of subjects: 16
Study 8640423 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual Child and Parent Cognitive‐Behavioral Treatment (CBT)
Number of subjects: 0
Study 8640423 — intervention group
Group type: COMPARATOR
Intervention: Family Therapy (FT)
Number of subjects: 0
Study 1575250 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine (up to 300 mg/day)
Number of subjects: 401
Study 1575250 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenelzine (up to 90 mg/day)
Number of subjects: 401
Study 1575250 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 401
Study 2857087 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostacyclin infusion (4-5 ng/kg/minute for 72 hours)
Number of subjects: 30
Study 2857087 — intervention group
Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 30
Study 2857087 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostacyclin infusion
Number of subjects: 30
Study 31392890 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibandronate
Number of subjects: 0
Study 31392890 — intervention group
Group type: COMPARATOR
Intervention: Vitamin D3
Number of subjects: 0
Study 28077047 — intervention group
Group type: COMPARATOR
Intervention: Standard infusion (SI) of cefepime 2g IV every 8h with 30-min infusion
Number of subjects: 63
Study 28077047 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended infusion (EI) of cefepime 2g IV every 8h with 3h infusion
Number of subjects: 63
Study 26899475 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived social support
Number of subjects: 790
Study 26899475 — intervention group
Group type: EXPERIMENTAL
Intervention: Hopefulness
Number of subjects: 790
Study 26899475 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotional regulation
Number of subjects: 790
Study 26899475 — intervention group
Group type: COMPARATOR
Intervention: Enacted stigma
Number of subjects: 790
Study 24449243 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin plus radiotherapy (CRT)
Number of subjects: 147
Study 24449243 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy alone (RT)
Number of subjects: 147
Study 22221937 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% to 20% preemptive warfarin dose reduction
Number of subjects: 37
Study 22221937 — intervention group
Group type: COMPARATOR
Intervention: Reactive warfarin dose adjustment
Number of subjects: 37